News | September 24, 2025
Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
The product is backed by required scientific proof and comparative bioequivalence studies
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
Subscribe To Our Newsletter & Stay Updated
